Evidence map›Paper›PMID 41004053›Full record

ReviewSub-cellular biochemistry2025

New Therapeutic Modalities in Prion Diseases.

Alberto Pettinari, Elisa Uliassi, Maria Laura Bolognesi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Sub-cellular biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alberto PettinariDepartment of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, Bologna, Italy.
Elisa UliassiDepartment of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, Bologna, Italy.
Maria Laura BolognesiDepartment of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, Bologna, Italy. marialaura.bolognesi@unibo.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prion diseases are fatal neurodegenerative disorders for which no effective therapies exist. Despite decades of drug discovery efforts, progress in developing disease-modifying treatments has been slow. However, recent advances have introduced novel therapeutic modalities targeting key aspects of prion pathology, including prion protein biogenesis, aggregation, and degradation. Advancements in diagnostic tools and highly sensitive prion detection methods are also playing a crucial role in enabling early and accurate diagnosis, which is essential for the timely application of emerging therapeutics. This chapter explores novel therapeutic modalities for prion diseases, focusing on small-molecule theranostics and compounds promoting prion protein degradation, RNA-based therapeutics, and gene therapy approaches. We critically assess the advantages and limitations of these therapeutic strategies, considering their development, efficacy, and translational potential. By leveraging these innovative modalities, the therapeutic toolbox for prion diseases is expanding, offering hope for the development of effective treatments.

Indexed as

Prion DiseasesPrion ProteinsGenetic TherapyHumansSmall Molecule LibrariesPrion ProteinsSmall Molecule LibrariesAntisense oligonucleotidesCellular prion protein (PrPC)Drug discoveryGene therapyNew therapeutic modalitiesPrion diseasesPrion protein (PrP)PrP degradationRNA aptamersRNA-based therapeuticsScrapie prion protein (PrPSc)Short interfering RNASmall-molecule theranostics

Identifiers

PMID41004053

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.